Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rupa Narayan

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Clinical and Vaccine Immunology : CVI|February 11, 2012
Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasisKevin W Bruhn, Ron Birnbaum, Jacquelyn Haskell, et al.
Leukemia & Lymphoma|September 17, 2015
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndromeRupa Narayan, Jacqueline S Garcia, Mary-Elizabeth M Percival, et al.
Integrative Cancer Therapies|June 13, 2013
A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinomaAbby B Siegel, Rupa Narayan, Rosa Rodriguez, et al.
Blood Advances|January 7, 2020
Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangementValentina Nardi, Nora Ku, Matthew J Frigault, et al.
The Journal of Investigative Dermatology|August 19, 2011
Immunomodulation by imiquimod in patients with high-risk primary melanomaRupa Narayan, Hong Nguyen, Jason J Bentow, et al.
Clinical and Translational Science|March 18, 2024
First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromeRupa Narayan, Ana Alfonso Piérola, William B Donnellan, et al.
Blood Advances|July 11, 2020
Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophiliaMonica Kasbekar, Valentina Nardi, Paola Dal Cin, et al.
Ejhaem|July 18, 2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignanciesJoan How, Siyang Ren, Jennifer Lombardi-Story, et al.
Blood|March 13, 2013
Multiple clinical forms of dehydrated hereditary stomatocytosis arise from mutations in PIEZO1Immacolata Andolfo, Seth L Alper, Lucia De Franceschi, et al.
Blood Advances|June 30, 2026
A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMMLAndrew M Brunner, Yiwen Liu, Jacqueline S Garcia, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Clinical and Vaccine Immunology : CVI|February 11, 2012
Killed but metabolically active Leishmania infantum as a novel whole-cell vaccine for visceral leishmaniasisKevin W Bruhn, Ron Birnbaum, Jacquelyn Haskell, et al.
Leukemia & Lymphoma|September 17, 2015
Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndromeRupa Narayan, Jacqueline S Garcia, Mary-Elizabeth M Percival, et al.
Integrative Cancer Therapies|June 13, 2013
A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinomaAbby B Siegel, Rupa Narayan, Rosa Rodriguez, et al.
Blood Advances|January 7, 2020
Clinical response to larotrectinib in adult Philadelphia chromosome-like ALL with cryptic ETV6-NTRK3 rearrangementValentina Nardi, Nora Ku, Matthew J Frigault, et al.
The Journal of Investigative Dermatology|August 19, 2011
Immunomodulation by imiquimod in patients with high-risk primary melanomaRupa Narayan, Hong Nguyen, Jason J Bentow, et al.
Clinical and Translational Science|March 18, 2024
First-in-human study of JNJ-67571244, a CD33 × CD3 bispecific antibody, in relapsed/refractory acute myeloid leukemia and myelodysplastic syndromeRupa Narayan, Ana Alfonso Piérola, William B Donnellan, et al.
Blood Advances|July 11, 2020
Targeted FGFR inhibition results in a durable remission in an FGFR1-driven myeloid neoplasm with eosinophiliaMonica Kasbekar, Valentina Nardi, Paola Dal Cin, et al.
Ejhaem|July 18, 2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignanciesJoan How, Siyang Ren, Jennifer Lombardi-Story, et al.
Blood|March 13, 2013
Multiple clinical forms of dehydrated hereditary stomatocytosis arise from mutations in PIEZO1Immacolata Andolfo, Seth L Alper, Lucia De Franceschi, et al.
Blood Advances|June 30, 2026
A Phase Ib/II study of ceralasertib, a selective inhibitor of ATR, in patients with relapsed or refractory MDS and CMMLAndrew M Brunner, Yiwen Liu, Jacqueline S Garcia, et al.
Pageof 3